Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-10-05
2010-10-05
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A
Reexamination Certificate
active
07807146
ABSTRACT:
The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.
REFERENCES:
patent: 6683059 (2004-01-01), Hung et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 2004/0141958 (2004-07-01), Steinaa et al.
patent: 2006/0008465 (2006-01-01), Steinaa et al.
patent: 2006/0240511 (2006-10-01), Eskling et al.
patent: 1188834 (2002-03-01), None
patent: 1188834 (2002-03-01), None
patent: 95/05849 (1995-03-01), None
patent: 2004/058278 (2004-07-01), None
patent: 2006/089690 (2006-08-01), None
Carroll et al. HIghly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: a Murine Tumor Model. Vaccine, vol. 15, No. 4, pp. 387-394.
Antonia et al., “Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer” Clin Cancer Res, 2006, 12:878-887.
Arlen et al., “Pox Viral Vaccine Approaches” Semin Oncology, 2005, 32:549-555.
Arlen et al., “A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer” Clin Cancer Res, 2006, 12:1260-1269.
Arlen et al., “A Randomized Phase II Study of Docetaxel Alone or in Combination with PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Patients with Metastatic Breast Cancer (NCI 05-C-0229)” Clinical Breast Cancer, 2006, 7:176-179.
Chong et al., “Combining cancer vaccines with chemotherapy” Expert Opinion Pharmacother, 2005, 2813-2820.
Chu et al., “Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma” J Immunother, 2006, 29:367-380.
Dela Cruz et al., “Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2
eu extracellular domain plus anti-HER2
eu IgG3-(IL-2) or anti-HER2
eu IgG3-(GM-CSF) fusion protein” Vaccine, 2005, 23:4793-4803.
Emens et al., “Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity” Endocrine-Related Cancer, 2005, 12:1-17.
Harrop et al., “Viral Vectors for Cancer Immunotherapy” Frontiers in Bioscience, 2006, 11:804-817.
Liu et al., “Gene-based vaccines and immunotherapeutics” Proc. Natl. Acad. Sci. USA, 2004, 101 (Suppl. 2):14567-14571.
Machiels et al., “Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2
eu Tolerized Mice” Cancer Research, 2001, 61:3689-3697.
Mittendorf et al., “Evaluation of the HER2
eu-Derived Peptide GP2 for Use in a Peptide-Based Breast Cancer Vaccine Trial” Cancer, 2006, 106:2309-2317.
Prell et al., “The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration” Cancer Immunol Immunother, 2006, 55:1285-1293.
Renard et al., “HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice” The Journal of Immunology, 2003, 171:1588-1595.
Rovero et al., “DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice” The Journal of Immunology, 2000, 165:5133-5142.
Sato et al., “Combination Docetaxel and Trastuzumab Treatment for Patients with HER-2-Overexpressing Metastatic Breast Cancer: A Multicenter, Phase-II Study” Breast Cancer, 2006, 13:166-171.
Triozzi et al., “Effect of Docetaxel Chemotherapy on the Activity of a Gonadotropin Releasing Hormone vaccine in Patients With Advanced Prostate Cancer” The Prostate, 2005, 65:316-321.
Yu et al., “Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer” Clinical Cancer Research, 2003, 9:285-294.
Burris et al., Doxetaxel (Taxotere) in HER-2-positive patients and in combination with Trastuzumab (Herceptin), Sem. In Oncology, 2000, 27:19-23.
Kastenmuller et al., Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of early transcription but distinct maturation-dependent cytopathogenicity, Virology, 2006, 350:276-288.
Mandl et al., MVA-BN-HER2: A novel vaccine for the treatment of breast cancers which overexpress HER-2, Journal of Immunotherapy, 2006, 29:652.
Merck Manuals Online Medical Library, Paclitaxel, Jan. 2009.
Merck Manuals Online Medical Library, Trastuzumab, Jan. 2009.
Merck Manuals Online Medical Library, Docetaxel, Jan. 2009.
Delcayre Alain
Laus Reiner
Mandl Stefanie
BN Immunotherapeutics, Inc.
Crouch Deborah
Law Office of Salvatore Arrigo
LandOfFree
Methods for treating cancer with a recombinant MVA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer with a recombinant MVA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer with a recombinant MVA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205630